Lenalidomide in solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 6, 2012, Pages 1393-1406

  Segler, Angela ^a   Tsimberidou, Apostolia Maria ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; Lenalidomide; Neuroendocrine; Response; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; BEVACIZUMAB; CALCITRIOL; CARBOPLATIN; DACARBAZINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IODINE 131; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; OXALIPLATIN; PACLITAXEL; PLACEBO; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SORAFENIB; TEMSIROLIMUS; THALIDOMIDE; TOPOTECAN; WARFARIN;

ABDOMINAL PAIN; ADVANCED CANCER; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; BLOOD CELL COUNT; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN CANCER; BRAIN ISCHEMIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CENTRAL NERVOUS SYSTEM TUMOR; COLON CANCER; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CONSTIPATION; CYTOKINE PRODUCTION; CYTOPENIA; DEPRESSION; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; ELECTROLYTE DISTURBANCE; FATIGUE; GLIOBLASTOMA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMANGIOENDOTHELIOMA; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOMODULATION; INFECTION; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY FAILURE; KIDNEY METASTASIS; LEUKOPENIA; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG CANCER; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MENTAL HEALTH; METASTASIS INHIBITION; MONOTHERAPY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; NONHUMAN; ONCOCYTOMA; OPTIC NERVE GLIOMA; OUTCOME ASSESSMENT; OVARY CANCER; OVARY CARCINOMA; PAIN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PARESTHESIA; PATIENT MONITORING; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PILOCYTIC ASTROCYTOMA; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEIN SYNTHESIS INHIBITION; REVIEW; SARCOMA; SIDE EFFECT; SKIN TOXICITY; SOLID TUMOR; SYNCOPE; T LYMPHOCYTE ACTIVATION; THORAX PAIN; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; THYROID CANCER; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; VOMITING; WEAKNESS; WEIGHT REDUCTION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; NEOPLASMS; THALIDOMIDE;

EID: 84863786691     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1874-2     Document Type: Review

References (68)

1. Knight R (2005) IMiDs: a novel class of immunomodulators. Semin Oncol 32(4 Suppl 5):S24-S30. doi:10.1053/j.seminoncol. 2005.06.018
2. Tohnya TM, Hwang K, Lepper ER, Fine HA, Dahut WL, Venitz J, Sparreboom A, Figg WD (2004) Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography- mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 811(2):135-141. doi:10.1016/j.jchromb.2004. 08.022
3. Muller GW, Chen R, Huang SY, Corral LG, Wong LM, Patterson RT, Chen Y, Kaplan G, Stirling DI (1999) Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 9(11):1625-1630
4. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163(1):380-386
5. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177(6):1675-1680
6. Melchert M, List A (2007) The thalidomide saga. Int J Biochem Cell Biol 39(7-8):1489-1499. doi:10.1016/j.biocel.2007.01.022
7. Stirling D (2001) Thalidomide: a novel template for anticancer drugs. Semin Oncol 28(6):602-606
8. Marriott JB, Clarke IA, Dredge K, Muller G, Stirling D, Dalgleish AG (2002) Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 130(1):75-84
9. Sharpe AH, Abbas AK (2006) T-cell costimulation-biology, therapeutic potential, and challenges. N Engl J Med 355(10): 973-975. doi:10.1056/ NEJMp068087
10. LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N, Mitsiades C, Cheema P, Chauhan D, Richardson PG, Anderson KC, Munshi NC (2004) Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 103(5): 1787-1790. doi:10.1182/blood-2003-02-0361
11. Dredge K, Marriott JB, Todryk SM, Muller GW, Chen R, Stirling DI, Dalgleish AG (2002) Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 168(10):4914-4919
12. Haslett PA, Corral LG, Albert M, Kaplan G (1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8? subset. J Exp Med 187(11):1885-1892
13. Teo SK (2005) Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J 7(1):E14-E19. doi: 10.1208/aapsj070103
14. Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, Verma A (2009) Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2:36. doi:10.1186/1756-8722-2-36
15. Wu L, Adams M, Parton S, Lu L, Schafer P, Bartlett JB, Celgene Corporation S, NJ (2010) Influence of NKG2D/DNAM-1 interaction with tumor cell ligands on the ability of lenalidomide to enhance ADCC of antibody-coated solid tumor cells. In: ASCO annual meeting, Chicago, IL, J Clin Oncol 28(suppl; abstr e21008)
16. Bartlett JB, Wu L, Adams M, Schafer P, Muller G, Stirling D (2007) Lenalidomide and pomalidomide strongly enhance tumor cell killing in vitro during antibody-dependent cellular cytotoxicity (ADCC) mediated by trastuzumab, cetuximab and rituximab. In: ASCO annual meeting, J Clin Oncol 25(18S, Part I):123s, Abstract #3023
17. Wu L, Parton A, Lu L, Adams M, Schafer P, Bartlett JB (2011) Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. Cancer Immunol Immunother 60(1):61-73. doi:10.1007/ s00262-010-0919-9
18. Blagosklonny MV (2004) Antiangiogenic therapy and tumor progression. Cancer Cell 5(1):13-17
19. Harris AL (2002) Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2(1):38-47. doi:10.1038/nrc704
20. Pouyssegur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441(7092):437-443. doi:10.1038/nature04871
21. Lu L, Schafer P, Bartlett JB, Celgene Corporation, Summit, NJ (2010) Effect of lenalidomide on hypoxia-induced HIF-1a signaling and the invasive phenotype in epithelial solid tumor cells. In: ASCO Annual Meeting Chicago, IL, J Clin Oncol
22. Liao D, Corle C, Seagroves TN, Johnson RS (2007) Hypoxiainducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 67(2):563-572. doi:10.1158/0008-5472.CAN- 06-2701
23. Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, Shirley MA, Muller G, Schafer P, Stirling D, Dalgleish AG, Bartlett JB (2005) Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69(1-2):56-63. doi:10.1016/j.mvr.2005.01.002
24. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, Schlossman RL, Richardson P, Ralph P, Wu L, Payvandi F, Muller G, Stirling DI, Anderson KC (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15(12):1950-1961
25. Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW, Chen RS, Muller GW, Hughes CCW, Stirling DI, Schafer PH, Bartlett JB (2009) The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 77(2):78-86. doi:10.1016/j.mvr.2008.08.003
26. Kataoka N, Iwaki K, Hashimoto K, Mochizuki S, Ogasawara Y, Sato M, Tsujioka K, Kajiya F (2002) Measurements of endothelial cell-to-cell and cell-to-substrate gaps and micromechanical properties of endothelial cells during monocyte adhesion. Proc Natl Acad Sci U S A 99(24):15638-15643. doi:10.1073/ pnas.242590799
27. Lin MT, Yen ML, Lin CY, Kuo ML (2003) Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. Mol Pharmacol 64(5):1029-1036. doi:10.1124/mol.64.5.1029
28. Matsumura T, Wolff K, Petzelbauer P (1997) Endothelial cell tube formation depends on cadherin 5 and CD31 interactions with filamentous actin. J Immunol 158(7):3408-3416
29. Osaki M, Oshimura M, Ito H (2004) PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9(6):667-676. doi:10.1023/B:APPT. 0000045801.15585.dd
30. Gandhi AK, Kang J, Naziruddin S, Parton A, Schafer PH, Stirling DI (2006) Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res 30(7):849-858. doi: 10.1016/j.leukres.2006.01.010
31. Tohnya T, Gulley J, Arlene P, Sparreboom A, Venitz J, Parker C, Fedenko K, Parnes H, Figg WD, Weber D (2006) Phase I study of lenalidomide, a novel thalidomide analog, in patients with refractory metastatic cancer, J Clin Oncol. ASCO annual meeting proceedings 24(18s, Part 1): 605s, Abstract # 13038
32. Bartlett JB, Michael A, Clarke IA, Dredge K, Nicholson S, Kristeleit H, Polychronis A, Pandha H, Muller GW, Stirling DI, Zeldis J, Dalgleish AG (2004) Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 90(5): 955-961. doi:10.1038/sj.bjc.6601579
33. Sharma RA, Steward WP, Daines CA, Knight RD, O'Byrne KJ, Dalgleish AG (2006) Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies. Eur J Cancer 42(14):2318-2325. doi:10.1016/j.ejca.2006.05. 018
34. Glaspy J, Atkins MB, Richards JM, Agarwala SS, O'Day S, Knight RD, Jungnelius JU, Bedikian AY (2009) Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. Cancer 115(22):5228-5236. doi:10.1002/cncr. 24576
35. Eisen T, Trefzer U, Hamilton A, Hersey P, Millward M, Knight RD, Jungnelius JU, Glaspy J (2010) Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer 116(1):146-154. doi:10.1002/cncr.24686
36. Hwu WJ, Knight RD, Patnana M, Bassett R, Papadopoulos NE, Kim KB, Hwu P, Bedikian A (2010) Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy. Melanoma Res 20(6):501-506. doi:10.1097/CMR.0b013e32833faf18
37. Sanborn SL, Gibbons J, Krishnamurthi S, Brell JM, Dowlati A, Bokar JA, Nock C, Horvath N, Bako J, Remick SC, Cooney MM (2009) Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors. Invest New Drugs 27(5):453-460. doi:10.1007/s10637-008-9200-x
38. Papadopoulos KMD, Preston GG, Lopez AM, Ricart AD, Schwartz G, Needle MN, Gordon MS (2005) A Phase I study of lenalidomide and weekly docetaxel in patients with advaced solid tumors. In: Proceedings of the AACR-NCI-EORTC international conference on molecular targets and cancer therapeutics, vol 11, no 24 Pt 2, p 215, Abstract #C71
39. Ain K, Lee C, Holbrook KM, Dziba JM, Williams KD (2008) Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine- unresponsive thyroid carcinomas: preliminary results. In: ASCO annual meeting, Chicago, IL, J Clin Oncol 26(May 20 suppl; abstr 6027)
40. Miller AA, Case D, Harmon M, Savage P, Lesser G, Hurd D, Melin SA (2007) Phase I study of lenalidomide in solid tumors. J Thorac Oncol 2(5):445-449. doi:10.1097/01.JTO.0000268679. 33238.67
41. Arkenau H, Infante JR, Bendell JC, Burris HA, Rubin MS, Waterhouse DM, Jones GT, Spigel DR (2011) Lenalidomide in combination with gemcitabine in patients with untreated metastatic carcinoma of the pancreas: A Sarah Cannon Research Institute phase II trial. In: ASCO annual meeting, J Clin Oncol 29(suppl; abstr e14640)
42. Liu WM, Nizar S, Dalgleish AG (2010) Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case study. Med Oncol 27(2):430-433. doi:10.1007/ s12032-009-9228-6
43. Zhang MM, Chan JK, Husain A, Guo HY, Teng NN (2007) Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma. Gynecol Oncol 105(1):194-198. doi:10.1016/j.ygyno.2006.11.026
44. Carter JS, Downs LS Jr (2011) A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma. Int J Clin Oncol. doi:10.1007/s10147-011-0243-1
45. Carter JS, Geller M, Judson P, Argenta P, Ghebre R, Jonson A, Carson L, Downs L (2011) A phase I study of lenalidomide in combination with liposomal doxorubicin in recurrent epithelial ovarian cancer. In: Proceedings of the 47th annual meeting of ASCO, Chicago, IL, J Clin Oncol 29(suppl; abstr e15545)
46. Sanborn SL, Cooney M, Gibbons J, Bokar JA, Nock CJ, Bako J, Horvath N, Tirgan NJ, Remick S (2008) Phase I trial of docetaxel given every three weeks and daily lenalidomide in patients with advanced solid tumors. Genitourinary cancers symposium abstract#183
47. Safran H, Charpentier K, Kaubisch A, Dubel G, Soares G, Faricy- Anderson KE, Miner TJ, Eng Y, Ribizzi-Akhtar I, Plette AM, Espat NJ, Berz D, Schumacher A, Luppe D, Bakalarski P, Wingate P, Victor J, Rosati K (2010) Lenalidomide for advanced hepatocellular cancer (HCC) in patients progressing on or intolerant to sorafenib. In: ASCO annual meeting, J Clin Oncol 28
48. Schilling G, Schuch G, Panse JP, Sterneck M, Bokemeyer C (2009) Activity of lenalidomide in metastatic hepatic epithelioid hemangioendothelioma (HEH): a case report. ASCO annual meeting (suppl; abstr e21527)
49. Henry JY, Lu L, Adams M, Meyer B, Bartlett JB, Dalgleish AG, Galustian C (2011) Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo. Prostate. doi: 10.1002/pros.21488
50. Zabransky DJ, Smith HA, Thoburn CJ, Zahurak M, Keizman D, Carducci M, Eisenberger MA, McNeel DG, Drake CG, Antonarakis ES (2011) Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. Prostate. doi:10.1002/pros.21449
51. Dahut WL, Aragon-Ching JB, Woo S, Tohnya TM, Gulley JL, Arlen PM, Wright JJ, Ventiz J, FiggWD(2009) Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol 49(6):650-660. doi:10.1177/0091270009335001
52. Lestingi TM, Tolzien K, Kelby SK, Nabhan C (2010) Safety and activity of lenalidomide (LEN) in elderly patients (pts) with chemotherapy-naive, castration-resistant prostate cancer (CRPC). ASCO annual meeting, vol 28, no suppl; abstr e15125
53. Petrylak DP, Resto-Garces K, Tibyan M, Mohile SG, Columbia University Medical Center NY, NY, University of Rochester R, NY (2009) A phase I open-label study using lenalidomide and docetaxel in castration-resistant prostate cancer. In: ASCO annual meeting, J Clin Oncol
54. Mathew P, Tannir N, Tu SM, Carter CM, Bekele NB, Pagliaro L (2010) A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy. Cancer Chemother Pharmacol 65(4):811-815. doi:10.1007/s00280-009-1237-9
55. Garcia J, Triozzi P, Smith S, Rini B, Gilligan T, Peereboom D, Elson P, Klein E, Dreicer R (2007) Phase I/II study of lenalidomide and GM-CSF in hormone refractory prostate cancer (HRPC). Prostate cancer symposium abstract #229
56. Garcia J, Triozzi P, Elson P, Cooney M, Tyler A, Gilligan T, Dreicer R (2008) Clinical activity of ketoconazole and lenalidomide in castrate progressive prostate carcinoma (CPPCA): preliminary results of a phase II trial. J Clin Oncol 26(May 20 suppl; abstr 5143)
57. Huang X, Ning YM, Mulquin M, Madan RA, Gulley JL, Kluetz PG, Adelberg D, Arlen PM, Parnes HL, Adesunloye B, Steinberg SM, Wright JJ, Trepel JB, Chen C, Bassim C, Apolo AB, Figg WD, Dahut WL (2011) Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (poster). In: ASCO annual meeting, J Clin Oncol 29(suppl; abstr 4574)
58. Amato RJ, Hernandez-McClain J, Saxena S, Khan M (2008) Lenalidomide therapy for metastatic renal cell carcinoma. Am J Clin Oncol 31(3):244-249. doi:10.1097/COC.0b013e31815e451f
59. Choueiri TK, Dreicer R, Rini BI, Elson P, Garcia JA, Thakkar SG, Baz RC, Mekhail TM, Jinks HA, Bukowski RM (2006) Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer 107(11):2609-2616. doi:10.1002/cncr.22290
60. Patel PH, Kondagunta GV, Schwartz L, Ishill N, Bacik J, DeLuca J, Russo P, Motzer RJ (2008) Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. Invest New Drugs 26(3):273-276. doi:10.1007/s10637-007- 9107-y
61. Mut M, Polar G, Carpenter JE, Redpath G, Larner J, Schiff D, Shaffrey ME (2007) Evaluation of lenalidomide activity on glioblastoma cell lines in vitro. J Neurol Sci 24(1):029-037
62. Warren KE, Goldman S, Pollack IF, Fangusaro J, Schaiquevich P, Stewart CF, Wallace D, Blaney SM, Packer R, Macdonald T, Jakacki R, Boyett JM, Kun LE (2011) Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. J Clin Oncol 29(3):324-329. doi:10.1200/ JCO.2010.31.3601
63. Fine HA, Kim L, Albert PS, Duic JP, Ma H, Zhang W, Tohnya T, Figg WD, Royce C (2007) A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Clin Cancer Res 13(23):7101-7106. doi:10.1158/1078-0432. CCR-07-1546
64. Drappatz J, Wong ET, Schiff D, Kesari S, Batchelor TT, Doherty L, Lafrankie DC, Ramakrishna N, Weiss S, Smith ST, Ciampa A, Zimmerman J, Ostrowsky L, David K, Norden A, Barron L, Sceppa C, Black PM, Wen PY (2009) A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 73(1): 222-227. doi:10.1016/j.ijrobp.2008.03.046
65. Kalmadi S, Davis M, Dowlati A, O'Keefe S, Cline-Burkhardt M, Pelley RJ, Borden E, Dreicer R, Bukowski R, Mekhail T (2007) Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors. Invest New Drugs 25(3):211-216. doi:10.1007/s10637-006- 9025-4
66. Shammo JM, Kassar M, Robin I, Knight R (2007) A case report of sarcoma regression in a patient with MDS treated with lenalidomide. In: ASCO annual meeting, J Clin Oncol
67. Brosseau C, Colston K, Bartlet B, Dalgleish AG, Galustian C, St Georges University of London L, United Kingdom, Celgene Corporation S, NJ (2010) The immunomodulatory drug lenalidomide restores a Vitamin D sensitive phenotype to the Vitamin D resistant breast cancer cell line MDA-MB-231. In: Proceedings of the American Association for Cancer Research, Washington, DC
68. Liu WM, Henry JY, Meyer B, Bartlett JB, Dalgleish AG, Galustian C (2009) Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs). Br J Cancer 101(5):803-812. doi:10.1038/sj.bjc.6605206